Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Off-label use in psychiatry].

M Weih1, N Thürauf, S Bleich

  • 1Psychiatrische und Psychotherapeutische Klinik, Universitätsklinikum Erlangen. markus.weih@uk-erlangen.de

Fortschritte Der Neurologie-Psychiatrie
|September 28, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sphingolipids in Emotional Well-Being.

Journal of neurochemistry·2026
Same author

Neural correlates of audiovisual integration in schizophrenia - an ERP study.

Frontiers in psychiatry·2024
Same author

Antipsychotic drug-induced neutropenia: results from the AMSP drug surveillance program between 1993 and 2016.

Journal of neural transmission (Vienna, Austria : 1996)·2023
Same author

Association between benzodiazepine receptor agonist use and mortality in patients hospitalised for COVID-19: a multicentre observational study.

Epidemiology and psychiatric sciences·2022
Same author

Acute Enterovirus Encephalitis as a Cause for Isolated Visual and Auditory Hallucinations in a 22-Year-Old Patient.

Case reports in psychiatry·2021
Same author

Galactorrhea during antipsychotic treatment: results from AMSP, a drug surveillance program, between 1993 and 2015.

European archives of psychiatry and clinical neuroscience·2021

Off-label drug use in psychiatry is rising, particularly for antidepressants and antipsychotics. Key concerns include safety, reimbursement, and care coordination, with new legal criteria for feasibility.

Area of Science:

  • Psychiatry
  • Pharmacology
  • Medical Law

Context:

  • Increasing prevalence of off-label prescribing for psychiatric medications, including antidepressants and antipsychotics.
  • Challenges associated with off-label use: drug safety, healthcare reimbursement issues, and fragmented care coordination.
  • Historical context of psychotropic drug approvals based on psychopathological phenomena rather than strict diagnostic categories.

Purpose:

  • To analyze the current landscape of off-label drug use in psychiatry.
  • To highlight the legal framework and criteria for off-label prescribing in Germany.
  • To underscore the importance of patient informed consent in off-label therapeutic decisions.

Summary:

  • Off-label prescribing of psychiatric drugs is a growing concern, presenting challenges in safety, reimbursement, and inter-professional collaboration.

Related Experiment Videos

  • German social legislation now permits off-label use under specific conditions, guided by recent court rulings.
  • Expert recommendations are anticipated, particularly for Methylphenidate in adult Attention-Deficit-Hyperactivity Disorder (ADHD).

    • Impact:

    • Informed consent is crucial for psychiatrists initiating off-label treatments.
    • The evolving legal and clinical guidelines aim to improve the safe and effective use of psychiatric medications.
    • This highlights the need for updated guidelines and better integration of off-label prescribing practices within psychiatric care.